Adult Acute Lymphoblastic Leukemia

Jabbour, Elias J.; Faderl, Stefan; Kantarjian, Hagop M .
November 2005
Mayo Clinic Proceedings;Nov2005, Vol. 80 Issue 11, p1517
Academic Journal
Much progress has been made in understanding the biology of and therapy for acute lymphoblastic leukemia (ALL). This progress has translated into the recognition of several subgroups of ALL and the Institution of risk-adapted therapies. New therapies are emerging based on the definition of specific cytogenetic-molecular abnormalities. Changes In the pathologic classification of ALL have led to therapeutic consequences. Adaptation of successful treatment strategies in children with ALL has resulted in similar complete remission rates in adults. Prognosis has improved especially in mature B-cell ALL and T-cell lineage ALL. However, regardless of ALL subgroup, long-term survival in adults is still inferior to that in children. Development of new drugs and agents tailored to subset-specific cytogenetic-molecular characteristics is vital to the therapeutic success in adult ALL.


Related Articles

  • l-Asparagine depletion levels and l-asparaginase activity in plasma of children with acute lymphoblastic leukemia under asparaginase treatment. Tsurusawa, Masahito; Chin, Motoaki; Iwai, Asayuki; Nomura, Keiko; Maeba, Hideaki; Taga, Takashi; Higa, Takeshi; Kuno, Tomoko; Hori, Toshinori; Muto, Akiko; Yamagata, Miyo // Cancer Chemotherapy & Pharmacology;Mar2004, Vol. 53 Issue 3, p204 

    Purpose. To determine the minimum levels of l-asparaginase (ASNase) activity necessary to maintain l-asparagine (Asn) depletion under ASNase treatment in acute lymphoblastic leukemia (ALL). Methods. We measured ASNase activity using an enzyme coupling method with a limit of detection of 2 U/l...

  • Induction death and treatment-related mortality in first remission of children with acute lymphoblastic leukemia: a population-based analysis of the Austrian Berlin-Frankfurt-Münster study group. Prucker, C.; Attarbaschi, A.; Peters, C.; Dworzak, M. N.; Pötschger, U.; Urban, C.; Fink, F.-M.; Meister, B.; Schmitt, K.; Haas, O. A.; Gadner, H.; Mann, G. // Leukemia (08876924);Jul2009, Vol. 23 Issue 7, p1264 

    In the management of the childhood acute lymphoblastic leukemia (ALL), 5% of failures are due to induction death and treatment-related deaths in first complete remission. We retrospectively analyzed the incidence, pattern and causes of death and its risk factors for 896 children with ALL...

  • Mercaptopurine.  // Reactions Weekly;11/11/2006, Issue 1127, p17 

    The article presents a case report of a 7-year-old boy who developed coagulation disorders during treatment with mercaptopurine as part of consolidation therapy for acute lymphoblastic leukemia. The consolidation therapy consisted of vincristine, dexamethasone, methotrexate and mercaptopurine....

  • Different molecular mechanisms causing 9p21 deletions in acute lymphoblastic leukemia of childhood. Novara, Francesca; Beri, Silvana; Bernardo, Maria Ester; Bellazzi, Riccardo; Malovini, Alberto Maria; Ciccone, Roberto; Cometa, Angela; Locatelli, Franco; Giorda, Roberto; Zuffardi, Orsetta // Human Genetics;Oct2009, Vol. 126 Issue 4, p511 

    Deletion of chromosome 9p21 is a crucial event for the development of several cancers including acute lymphoblastic leukemia (ALL). Double strand breaks (DSBs) triggering 9p21 deletions in ALL have been reported to occur at a few defined sites by illegitimate action of the V(D)J recombination...

  • Very early/early relapses of acute lymphoblastic leukemia show unexpected changes of clonal markers and high heterogeneity in response to initial and relapse treatment. Eckert, C.; Flohr, T.; Koehler, R.; Hagedorn, N.; Moericke, A.; Stanulla, M.; Kirschner-Schwabe, R.; Cario, G.; Stackelberg, Av.; Bartram, C. R.; Henze, G.; Schrappe, M.; Schrauder, A. // Leukemia (08876924);Aug2011, Vol. 25 Issue 8, p1305 

    Minimal residual disease (MRD) quantified after induction treatment of childhood acute lymphoblastic leukemia (ALL) predicts risk of relapse. It has been assumed that early relapses derive from a residual population of leukemic cells, which is still present after induction and that relapsed...

  • Granulocyte colony-stimulating factor receptor expression and 11q23/MLL genotype in childhood acute lymphoblastic leukemia developing during the first 18 months of life. Stanulla, M; Kasper, B; Schrappe, M; Viehmann, S; Harbott, J; Ludwig, W-D; Welte, K // Leukemia (08876924);Feb2000, Vol. 14 Issue 2, p337 

    Focuses on the role of granulocyte colony-stimulating factor (G-CSF) receptor expression in acute lymphoblastic leukemia (ALL) in children. Case history of a 20-month old boy with ALL; Analysis of G-CSF receptor expression in eight ALL patients; Flow cytometric analysis of G-CSF receptor...

  • Medical cost of curing childhood acute lymphoblastic leukaemia. Wheeler, Kate; Leiper, Alison D.; Jannoun, Leila; Chessells, Judith M. // British Medical Journal (Clinical Research Edition);1/16/1988, Vol. 296 Issue 6616, p162 

    Examines the diagnosis of children with acute lymphoblastic leukemia in London, England. Application of craniospinal irradiation for treating the disease; Conduction of central nervous system relapse as a combination of irradiation treatment; Number of irradiation after bone marrow transplant.

  • Acute Lymphoblastic Leukemia in Children. Cagen, Deborah; Franco, Michelle // Clinical Journal of Oncology Nursing;Sep/Oct2003, Vol. 7 Issue 5, p604 

    Presents a quiz on acute lymphoblastic leukemia in children. Diagnosis; Treatment options.

  • Congenital acute lymphoblastic leukemia: a two-case report and a review of the literature. Suárez, Ma Pilar Bas; Brito, Jezabel López; Reyes, Candelaria Santana; Muñoz, Manuel Gresa; Pulido, Rosario Diaz; Rojas, Jose Carlos Lodos // European Journal of Pediatrics;Apr2011, Vol. 170 Issue 4, p531 

    Congenital leukemia is a rare disease with particular biological and clinical characteristics which differs from those of older children and adults. Here, we describe two cases of congenital acute lymphoblastic leukemia in two newborns with different clinical presentations (leukemia cutis vs....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics